Compare Ginkgo Bioworks Holdings Inc (DNA) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs SiTime Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while SiTime Corporation trades at $690.43 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 39.6× Ginkgo Bioworks Holdings Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | SITM | |
|---|---|---|
Market Cap | $505.73M | $20.05B |
Sector | Health | Technology |
52-Week High | $16.14 | $901.60 |
52-Week Low | $5.48 | $212.77 |
Enterprise Value | $607.68M | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
SiTime Corporation (SITM) trades at $697.50, up 1.09% with strong bullish technical signals and consistent earnings beats. The stock shows robust revenue growth, expanding margins, and positive analyst sentiment with a $870 consensus price target. Recent Q2 2026 results exceeded expectations with 127% revenue growth, driven by AI infrastructure demand and the Renesas acquisition.
Outlook remains positive with AI timing growth as the key catalyst, though premium valuation and integration risks warrant caution. The stock offers significant upside potential from current levels but faces execution risks in scaling operations and maintaining margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
